Clinical Trials · NCT01013506
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Withdrawn
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Enrollment
- 0
- Start date
- Aug 2009
- Locations
- See registry
- Primary endpoint
- Time to progression